Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

NCT01980277 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

68

Enrollment

OTHER

Sponsor class

Stopped Drug development stopped

Conditions

Breast Cancer

Interventions

DRUG: LY2780301 + paclitaxel

Sponsor

Institut Paoli-Calmettes